Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection

Stuart Dowall; Jo Callan; Antra Zeltina; Ibrahim Al-Abdulla; Thomas Strecker; Sarah K. Fehling; Verena Krähling; Andrew Bosworth; Emma Rayner; Irene Taylor; Sue Charlton; John Landon; Ian Cameron; Roger Hewson; Abdulsalami Nasidi; Thomas A. Bowden; Miles Carroll

doi:10.1093/infdis/jiv565

Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection

Stuart Dowall, Jo Callan, Antra Zeltina, Ibrahim Al-Abdulla, Thomas Strecker, Sarah K. Fehling, Verena Krähling, Andrew Bosworth, Emma Rayner, Irene Taylor, Sue Charlton, John Landon, Ian Cameron, Roger Hewson, Abdulsalami Nasidi, Thomas A. Bowden, Miles Carroll^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo Guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of Guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.

Original language	English
Pages (from-to)	1124-1133
Number of pages	10
Journal	Journal of Infectious Diseases
Volume	213
Issue number	7
DOIs	https://doi.org/10.1093/infdis/jiv565
Publication status	Published - 1 Apr 2016

Bibliographical note

Publisher Copyright:
© The Author 2015.

Keywords

Antibody
Ebola
Efficacy
Neutralization
Therapeutic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jiv565

Cite this

Dowall, S., Callan, J., Zeltina, A., Al-Abdulla, I., Strecker, T., Fehling, S. K., Krähling, V., Bosworth, A., Rayner, E., Taylor, I., Charlton, S., Landon, J., Cameron, I., Hewson, R., Nasidi, A., Bowden, T. A., & Carroll, M. (2016). Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection. Journal of Infectious Diseases, 213(7), 1124-1133. https://doi.org/10.1093/infdis/jiv565

@article{ff6cccf0a4b34dee9d508e5afa5fda10,

title = "Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection",

abstract = "The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo Guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of Guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.",

keywords = "Antibody, Ebola, Efficacy, Neutralization, Therapeutic",

author = "Stuart Dowall and Jo Callan and Antra Zeltina and Ibrahim Al-Abdulla and Thomas Strecker and Fehling, {Sarah K.} and Verena Kr{\"a}hling and Andrew Bosworth and Emma Rayner and Irene Taylor and Sue Charlton and John Landon and Ian Cameron and Roger Hewson and Abdulsalami Nasidi and Bowden, {Thomas A.} and Miles Carroll",

note = "Publisher Copyright: {\textcopyright} The Author 2015.",

year = "2016",

month = apr,

day = "1",

doi = "10.1093/infdis/jiv565",

language = "English",

volume = "213",

pages = "1124--1133",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "7",

}

Dowall, S, Callan, J, Zeltina, A, Al-Abdulla, I, Strecker, T, Fehling, SK, Krähling, V, Bosworth, A, Rayner, E, Taylor, I, Charlton, S, Landon, J, Cameron, I, Hewson, R, Nasidi, A, Bowden, TA & Carroll, M 2016, 'Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection', Journal of Infectious Diseases, vol. 213, no. 7, pp. 1124-1133. https://doi.org/10.1093/infdis/jiv565

TY - JOUR

T1 - Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection

AU - Dowall, Stuart

AU - Callan, Jo

AU - Zeltina, Antra

AU - Al-Abdulla, Ibrahim

AU - Strecker, Thomas

AU - Fehling, Sarah K.

AU - Krähling, Verena

AU - Bosworth, Andrew

AU - Rayner, Emma

AU - Taylor, Irene

AU - Charlton, Sue

AU - Landon, John

AU - Cameron, Ian

AU - Hewson, Roger

AU - Nasidi, Abdulsalami

AU - Bowden, Thomas A.

AU - Carroll, Miles

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo Guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of Guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.

AB - The highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the humoral host response. Recombinant EBOV-GP ectodomain (EBOV-GP1,2ecto) expressed in mammalian cells was used to immunize sheep and elicited a robust immune response and produced high titers of high avidity polyclonal antibodies. Investigation of the neutralizing activity of the ovine antisera in vitro revealed that it neutralized EBOV. A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared from the antisera and used for an in vivo Guinea pig study. When EBOTAb was delivered 6 hours after challenge, all animals survived without experiencing fever or other clinical manifestations. In a second series of Guinea pig studies, the administration of EBOTAb dosing was delayed for 48 or 72 hours after challenge, resulting in 100% and 75% survival, respectively. These studies illustrate the usefulness of EBOTAb in protecting against EBOV-induced disease.

KW - Antibody

KW - Ebola

KW - Efficacy

KW - Neutralization

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=84962549897&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv565

DO - 10.1093/infdis/jiv565

M3 - Article

C2 - 26715676

AN - SCOPUS:84962549897

SN - 0022-1899

VL - 213

SP - 1124

EP - 1133

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 7

ER -

Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this